赛托生物：子公司收到甲泼尼龙化学原料药上市申请批准通知书

Core Viewpoint - The announcement indicates that the company's subsidiary, Shandong Sry Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of Methylprednisolone, a corticosteroid used in various critical medical conditions [1] Group 1: Product Approval - Shandong Sry Pharmaceutical has been granted a marketing approval notice for Methylprednisolone [1] - Methylprednisolone is classified as a medium-acting, non-halogenated corticosteroid [1] Group 2: Medical Applications - The drug is utilized for emergency treatment in critical illnesses [1] - It is also indicated for endocrine disorders, rheumatic diseases, collagen diseases, skin diseases, allergic reactions, ophthalmic diseases, gastrointestinal diseases, hematological diseases, leukemia, shock, cerebral edema, multiple neuritis, myelitis, and to prevent vomiting caused by cancer chemotherapy [1]